Comments

You must log in or register to comment.

Ezekiel_W OP t1_irxa6nl wrote

>By packaging lipid nanoparticles with elements that decrease the fibrous nature of solid tumors, researchers can deliver CRISPR therapies in a more efficient manner.
>
>In a paper recently published in Nature Nanotechnology, Siegwart and his team developed a dual approach using LNPs equipped with tools that allow them to access and modify the tumor.4 The researchers packaged the LNPs with a CRISPR-Cas9 system that genetically modified and disrupted PD-L1 gene expression. PD-L1 overexpression inhibits T cell infiltration within the tumor microenvironment, so deactivating the gene allows immune cells to access the tumor. To grant the CRISPR system and immune cells tumor access, the LNP also included siRNA that targeted and reduced the expression of focal adhesion kinase (FAK), which diminished the density of the extracellular matrix surrounding the tumor.

This is really good news. One of the biggest challenges with mRNA and CRISPR therapies for cancer treatments is penetrating solid tumors.

12

Necessary-Celery t1_irymyjb wrote

Great news. Just the idea we might revert existing tumors to healthy cells, with one injection, is crazy to ponder.

3

Solrokr t1_irxlye7 wrote

Iā€™m curious how this will practically change medical practice. Good share.

2

Scope_Dog t1_is1th5z wrote

ok, I feel like this is a big deal. Is this a big deal? How is this not a magic bullet?

2

Ezekiel_W OP t1_is1umsb wrote

We are still learning a lot and improving things with CRISPR and mRNA tech, the real magic happens a little later this decade.

5

FuturologyBot t1_irxfoj6 wrote

The following submission statement was provided by /u/Ezekiel_W:

>By packaging lipid nanoparticles with elements that decrease the fibrous nature of solid tumors, researchers can deliver CRISPR therapies in a more efficient manner.
>
>In a paper recently published in Nature Nanotechnology, Siegwart and his team developed a dual approach using LNPs equipped with tools that allow them to access and modify the tumor.4 The researchers packaged the LNPs with a CRISPR-Cas9 system that genetically modified and disrupted PD-L1 gene expression. PD-L1 overexpression inhibits T cell infiltration within the tumor microenvironment, so deactivating the gene allows immune cells to access the tumor. To grant the CRISPR system and immune cells tumor access, the LNP also included siRNA that targeted and reduced the expression of focal adhesion kinase (FAK), which diminished the density of the extracellular matrix surrounding the tumor.

This is really good news. One of the biggest challenges with mRNA and CRISPR therapies for cancer treatments is penetrating solid tumors.

Please reply to OP's comment here: https://old.reddit.com/r/Futurology/comments/y1h0xb/researchers_develop_a_crisprbased_therapy_that/irxa6nl/

1

Snortykins t1_irz8xn8 wrote

Have the core safety issues concerning crispr been addressed yet? Like, at all?

1

Ezekiel_W OP t1_irz9ioa wrote

That would depend on what you mean.

4

Snortykins t1_irzazrd wrote

I mean the amount of damage being done to non-target genes

1

Ezekiel_W OP t1_irzbnna wrote

Then the answer is yes, it has.

5